American Society of Clinical Oncology
225 Reinekers Lane
2074 articles with American Society of Clinical Oncology
Novartis flexed its clinical muscles over the weekend, announcing results from multiple studies including different types of cancer and kidney disease.
Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting
Survival benefit observed in two treatment settings of previously treated non-small lung cancer patients
With the 2021 American Society of Clinical Oncology Annual Meeting now in high gear, there is plenty of news. Here’s a look at just some of the most recent stories.
ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021
ImmVira will present results from its clinical Phase I study of MVR-T3011 via intratumoral administration at the 2021 American Society of Clinical Oncology Annual Meeting on June 4-8, 2021 for the first time.
Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
New data from across Eli Lilly and Company's oncology portfolio will be presented at the 2021 American Society of Clinical Oncology Annual Meeting, held June 4-8, 2021.
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel, at the American Society of Clinical Oncology congress.
The FDA further delays Iovance’s filing for its TIL therapy as it requests additional data on the treatment’s potency assays.
Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer
Amcenestrant, an investigational oral selective estrogen receptor degrader (SERD), achieved an objective response rate of 34% and a clinical benefit rate of 74% in Phase 1 study (AMEERA-1) in combination with palbociclib
Over 20 studies to be presented at ASCO, featuring data from leading cancer research institutions across the U.S. in partnership with Caris Life Sciences, highlighting Caris' innovative technology and robust clinico-genomic database.
Study validates Syapse’ Composite Mortality Score methodology and its ability to overcome disparities driven by social determinants of health in the capture of mortality in the real-world setting.
New England Journal of Medicine Publishes Final Data for NUBEQA®(darolutamide) Plus Androgen Deprivation Therapy Showing a Statistically Significant Improvement in Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer
The New England Journal of Medicine published the full overall survival results from the pre-specified final OS analysis of the Phase III ARAMIS trial for NUBEQA® in men with non-metastatic castration-resistant prostate cancer.
American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer
Myriad Genetics, Inc., a global leader in molecular diagnostics and precision medicine, announced that the American Society of Clinical Oncology has exclusively included Myriad’s myChoice® CDx test in its new recommendations on the use of PARP inhibitors for the treatment and management of certain patients with advanced ovarian cancer.
The American Society of Clinical Oncology 2020 meeting was held virtually this year due to the COVID-19 pandemic. As usual, there were literally hundreds of abstracts, posters and presentations. Here’s a look at some of the highlights.
MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL‑CEBPA in Combination with Sorafenib in Liver Cancer at 2020 ASCO Annual Meeting
Observed clinical activity, including durable and complete tumour responses, suggests that MTL‑CEBPA may increase the effectiveness of sorafenib standard of care
Harpoon Therapeutics to Present Interim Clinical Data for TriTAC® HPN424 at the ASCO20 Virtual Scientific Program
Management to host webcast and conference call to review interim Phase 1 data and provide a pipeline update at 4 p.m. ET /1 p.m. PT on May 29, 2020
BostonGene Announces Acceptance of Abstracts to the Annual Meeting of the American Society of Clinical Oncology 2020
Abstracts Underscore the Results of Collaborations with Multiple Leading Cancer Centers in the United States
Kleo Pharmaceuticals to Present Preclinical Data Highlighting the Synergistic Potential of Kleo Asset KP1237 and Autologous NK Cells in the Treatment of Multiple Myeloma at the 2020 American Society of Clinical Oncology Virtual Meeting
Data support the initiation of an upcoming first-in-human trial for first-line, MRD+ multiple myeloma patients post-ASCT
Two-year follow-up for first-in-class bifunctional immunotherapy bintrafusp alfa‡ targeting TGF-β/PD-L1, in second-line NSCLC
Tiziana Life Sciences Announces Data Demonstrating StemPrintER’s Superiority Compared to Oncotype DX in Providing Prognostic Informat to Conventional Clinical Parameters in Breast Cancer Patients in Poster Discussion Session at the ASCO
Additional data to be presented validating the SPARE Model for Distant Metastasis Prediction utilizing the Company’s StemPrintER Platform
New data for Sarclisa® (isatuximab-irfc) and Jevtana® (cabazitaxel) in difficult-to-treat cancers reinforce breadth and depth of portfolio